Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Kircik LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani AR, Draelos ZD, DuBois J, Gooderham MJ, Kempers SE, Lain E, Lee M, Moore A, Murrell DF, Papp KA, Pariser DM, Sinclair R, Zirwas M, Burnett P, Higham RC, Krupa D, Berk DR. Kircik LH, et al. Among authors: dubois j. Br J Dermatol. 2023 Sep 15;189(4):392-399. doi: 10.1093/bjd/ljad182. Br J Dermatol. 2023. PMID: 37279795 Clinical Trial.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G. Stein-Gold L, et al. Among authors: dubois j. J Am Acad Dermatol. 2018 Jan 31:S0190-9622(18)30147-6. doi: 10.1016/j.jaad.2018.01.028. Online ahead of print. J Am Acad Dermatol. 2018. Retraction in: J Am Acad Dermatol. 2019 Feb;80(2):579. doi: 10.1016/j.jaad.2018.04.011 PMID: 29409915 Free article. Retracted.
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
Stein-Gold L, Kircik L, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg D, Kaufman J, Tanghetti E, Ahluwalia G, Alvandi N, Weng E, Berk D. Stein-Gold L, et al. Among authors: dubois j. J Drugs Dermatol. 2018 Nov 1;17(11):1201-1208. J Drugs Dermatol. 2018. PMID: 30500142 Clinical Trial.
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
Kirsch B, Smith S, Cohen J, DuBois J, Green L, Baumann L, Bhatia N, Pariser D, Liu PY, Chadha D, Walker P. Kirsch B, et al. Among authors: dubois j. J Am Acad Dermatol. 2020 Jun;82(6):1321-1327. doi: 10.1016/j.jaad.2020.02.016. Epub 2020 Feb 15. J Am Acad Dermatol. 2020. PMID: 32068049 Clinical Trial.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Blauvelt A, et al. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040. N Engl J Med. 2021. PMID: 33567191 Clinical Trial.
1,978 results